Parexel, a U.S.-based contract research organization (CRO), has entered into a partnership with Shanghai Ruijin Hospital’s Hainan subsidiary. This collaboration aims to explore the use of real-world data (RWD) and real-world evidence (RWE) to facilitate the accelerated approval of drugs, thereby increasing Chinese patients’ access to innovative medications and therapies.
The RWE regulatory pathway in Hainan permits manufacturers to leverage RWD/E in their market applications for drugs and devices in China. This process is designed to shorten the time it takes for new medical products to reach the market, addressing unmet medical needs in China more swiftly.- Flcube.com
